Jeffrey Farrow was appointed Director of Lisata Therapeutics, Inc. As of November 6, 2026, Lisata Therapeutics, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from August 4, 2026 to October 14, 2026, naming 2 appointments (Form 8-K, October 14, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Lisata Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Jeffrey Farrow · Role: Director · 8-K, 2026-10-14
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-09-17
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-08-04
Lisata Therapeutics, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-08-04 to 2026-10-14. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Lisata Therapeutics, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2026-08-04 (layoff filings and notices).
Also on the record for Lisata Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 2, 2026 | Form D, private offering | $351.90M sold | Form D page | Source |
| September 17, 2026 | Acquired Marea Therapeutics, Inc. | $225M | Acquisition | Source |
| August 26, 2026 | Stake report, Schedule 13G, by Branham Justin Earl | 5.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Lisata Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Lisata Therapeutics, Inc. and the records around it.
Lisata Therapeutics, Inc. elsewhere on the record
- Form D filing Oct 2026
- Acquisition Sep 2026
- Layoff notices Aug 2026
- Who owns it
Watch Lisata Therapeutics, Inc.
Get an email when Lisata Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lisata Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Lisata Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lisata Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-14 | In | Director | 8-K, 2026-10-14 | ||
| 2026-10-14 | In | 8-K, 2026-10-14 | |||
| 2026-09-17 | Reported | not named in the filing | 8-K, 2026-09-17 | ||
| 2026-08-04 | Reported | not named in the filing | 8-K, 2026-08-04 |
Who leads Lisata Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Jeffrey Farrow, appointed (filed 2026-10-14).
New leaders reset buying decisions — get the Full Report on Lisata Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Lisata Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Lisata Therapeutics, Inc.Every change, in the filing's words
Appointed: Jeffrey Farrow, Director
(d) On October 13, 2026, upon the recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the "Board") of Lisata Therapeutics, Inc. (the "Company") approved an increase in the size of the Board from seven to eight members and appointed Jeffrey Farrow as a Class III member of the Board to fill the newly created seat effective immediately, with an initial term expiring at the Company's 2028 annual meeting of stockholders.
Appointed: Jeffrey Farrow
The Board also appointed Mr. Farrow as a member of the Audit Committee.
- Jeffrey Farrow (Age 65) has served as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics in eye care and beyond, since April 2023.
- Mr. Farrow has also served as a director of Clover Biopharmaceuticals, Ltd., a development stage biotechnology company listed on the Hong Kong Stock Exchange, since September 2021 and a director, chairperson of the audit committee and member of the nominating and corporate governance committee of Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late stage specialty pharmaceutical company, since May 2026.
- Mr. Farrow previously served as Chief Financial Officer of Global Blood Therapeutics, Inc. (formerly Nasdaq: GBT), a biopharmaceutical company, from April 2016 until December 2022 when it was acquired by Pfizer Inc. Prior to that, Mr. Farrow served as chief financial officer of ZS Pharma, Inc., a biopharmaceutical company, which was acquired by AstraZeneca in December 2015.
- Prior to ZS Pharma, he served as the chief financial officer at Hyperion Therapeutics, Inc., a commercial pharmaceutical company, from July 2010 until May 2015 which was acquired by Horizon Therapeutics in May 2015.
- He previously served as vice president of finance at Evotec AG, a drug discovery and development company.
Reported
Appointment of Director In accordance with the Merger Agreement, on September 17, 2026 , effective immediately after the First Effective Time, Ted W. Love, M.D. was appointed to the Board as a director.
- - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- Prior to the Merger, Dr. Love served as the Chairman of the board of directors of Marea since May 2023.
- Since June 2025, Dr. Love has served as the Immediate Past Chairman of the board of directors of the Biotechnology Innovation Organization, a trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other countries.
- From June 2014 to October 2022, Dr. Love was the President and Chief Executive Officer of Global Blood Therapeutics, Inc. (formerly Nasdaq: GBT, a publicly traded biopharmaceutical company acquired by Pfizer, Inc.), where he led the company from a pre-clinical startup through its growth to a global commercial company with a pipeline of innovative therapies focused on sickle cell disease.
- Previously, he was Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc. He also served as President, Chief Executive Officer and Chairman of Nuvelo, Inc., and Senior Vice President, Development at Theravance Biopharma, Inc. (Nasdaq:TBPH).
Reported
In connection with the reduction in workforce approved by the Board on August 3, 2026, effective as of August 3, 2026, the employment of Dr. Kristen K. Buck, M.D., the Company's Executive Vice President of R&D and Chief Medical Officer was terminated.
- In addition, on August 3, 2026, the Board approved a cash retention bonus to James Nisco, the Company's Senior Vice President, Finance and Treasury and Chief Accounting Officer, in the amount of $200,000.
- The cash bonus is payable within thirty (30) days of, and subject to continued employment with the Company through, December 31, 2026; provided that if the applicable executive's employment is terminated by the Company without "Cause", then the retention bonus shall be payable within thirty (30) days of the executive's execution and non-revocation of a release of claims.
Tools for this story
Each opens in a new tab, filled in for Lisata Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.